Treatment-Resistant Depression Diagnosis Threshold
A patient must fail at least two adequate antidepressant trials before being diagnosed with treatment-resistant depression (TRD). This represents the most widely accepted and evidence-based definition, endorsed by both the FDA and EMA, and supported by strong consensus (96%) in the most recent Delphi-method guideline 1.
Core Diagnostic Criteria
The 2022 Molecular Psychiatry consensus guideline establishes that TRD requires:
- Minimum of two failed antidepressant treatments with less than 25% symptom improvement 1
- Both failures must occur within the current depressive episode (weak consensus, 51%) 1
- For prolonged episodes, only treatment failures within the last two years should be considered 1
What Constitutes an "Adequate" Trial
Each failed trial must meet specific adequacy criteria:
- Dose: Minimum approved therapeutic dosage for that medication 1
- Duration: At least 4 weeks of treatment at adequate dose 1, 2
- Adherence: Documented compliance with the prescribed regimen 1
- Documentation: Properly verified through pharmacy records, hospital records, or other clinical documentation—not just patient recall 1
Critical pitfall: Approximately 50% of apparent TRD cases are actually "pseudo-resistant" due to inadequate dose, insufficient duration, or non-adherence 3. Always verify treatment adequacy before labeling a patient as treatment-resistant.
Partial Response vs. Treatment Resistance
The guidelines distinguish between two categories:
- TRD (Treatment-Resistant Depression): Less than 25% improvement after two adequate trials 1
- PRD (Partial-Resistant Depression): 25-50% improvement after even a single adequate trial (moderate consensus, 76%) 1
This distinction matters because PRD patients may respond to augmentation strategies, while TRD patients typically require more aggressive interventions.
Clinical Context and Nuances
Episode Timing Matters
The requirement that both failures occur within the current episode reflects weak consensus (51%) 1. The expert panel was divided between those wanting a shorter timeframe and those accepting lifetime failures. The two-year window for long episodes represents a middle-ground compromise 1.
Treatment Class Requirements
The two failed medications should ideally be from different pharmacologic classes with different mechanisms of action (moderate consensus, 75%) 1. This ensures genuine resistance rather than inadequate exploration of treatment options.
What Doesn't Count as a Failed Trial
- Discontinuation before completing 4 weeks without clear evidence of non-response (strong consensus, 96%) 1
- Failed psychotherapy alone (strong consensus, 100%) 1
- Treatments where adherence cannot be documented 1
Real-World Application
Despite clear guidelines, clinical practice often deviates from this standard. A 2020 systematic review found that only 19% of TRD studies actually required two prior failures with confirmed adequate dose and duration 2. Many studies used just one prior failure (48% of studies) 2, highlighting inconsistency between research definitions and guideline recommendations.
For clinical practice: Use the two-failure threshold with documented adequacy. This aligns with regulatory standards (FDA/EMA) 1, 3, represents the most common definition in the literature 1, and has the strongest expert consensus (96%) 1.
Associated Risk Factors
Once TRD is established, be aware that these patients have significantly higher rates of:
- Recurrent depression (OR 1.24) 4
- Comorbid anxiety disorders (OR 1.21) 4
- Personality disorders (OR 1.35) 4
- Self-harm (OR 1.76) 4
- Cardiovascular disease (OR 1.46) 4
- Economic inactivity and functional decline 4
These factors should trigger more intensive monitoring and comprehensive treatment planning beyond simple medication trials.